Topics:
Hematologic Malignancies • Medical Oncology • Lymphoma • NCI-CCC Tumor Board Question • University of Michigan • Hematology • NCI-CCC Lymphoma Tumor Board Question
How would you manage a patient with history of follicular lymphoma treated with Bendamustine-Rituximab who now has a new FDG avid lesion that is biopsy proven CD30 positive CD20 negative DLBCL?
Answer from: Medical Oncologist at Academic Institution
Certainly an unusual and challenging situation, and one that raises multiple questions. How long ago was the rituximab - is the CD20- status "true" or might it be a false-negative in the presence of blocking antibodies? Is it really totally negative or rare/dim?But taking at face value that the dise...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
I agree with Dr. @Matthew J. Matasar. If the patient is young/fit and the duration of remission was < 2 years, I would use CHOP x 3-4 cycles and consolidation with autologous stem cell transplant. Also agree that brentuximab vedotin is known to have clinical activity here as a single agent (Jacob...